Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABCA1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ABCA1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ABCA1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ABCA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ABCA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABCA1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00324969 | Cervix | CC | response to lipopolysaccharide | 74/2311 | 343/18723 | 9.15e-07 | 3.25e-05 | 74 |
GO:003133410 | Cervix | CC | positive regulation of protein-containing complex assembly | 55/2311 | 237/18723 | 2.25e-06 | 6.73e-05 | 55 |
GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00465785 | Cervix | CC | regulation of Ras protein signal transduction | 44/2311 | 189/18723 | 2.05e-05 | 3.73e-04 | 44 |
GO:00301008 | Cervix | CC | regulation of endocytosis | 47/2311 | 211/18723 | 3.65e-05 | 5.82e-04 | 47 |
GO:00458077 | Cervix | CC | positive regulation of endocytosis | 27/2311 | 100/18723 | 5.55e-05 | 8.10e-04 | 27 |
GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
GO:00350235 | Cervix | CC | regulation of Rho protein signal transduction | 22/2311 | 86/18723 | 5.93e-04 | 5.60e-03 | 22 |
GO:00714042 | Cervix | CC | cellular response to low-density lipoprotein particle stimulus | 9/2311 | 22/18723 | 7.19e-04 | 6.49e-03 | 9 |
GO:00712228 | Cervix | CC | cellular response to lipopolysaccharide | 41/2311 | 209/18723 | 1.69e-03 | 1.29e-02 | 41 |
GO:00094109 | Cervix | CC | response to xenobiotic stimulus | 78/2311 | 462/18723 | 2.39e-03 | 1.70e-02 | 78 |
GO:00712168 | Cervix | CC | cellular response to biotic stimulus | 46/2311 | 246/18723 | 2.53e-03 | 1.76e-02 | 46 |
GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
GO:00712198 | Cervix | CC | cellular response to molecule of bacterial origin | 42/2311 | 221/18723 | 2.79e-03 | 1.87e-02 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541722 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa0541732 | Liver | Cirrhotic | Lipid and atherosclerosis | 80/2530 | 215/8465 | 1.18e-02 | 3.81e-02 | 2.35e-02 | 80 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa020102 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
hsa0541742 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa020103 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
hsa0541752 | Liver | HCC | Lipid and atherosclerosis | 118/4020 | 215/8465 | 1.66e-02 | 3.92e-02 | 2.18e-02 | 118 |
hsa0541730 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
hsa05417113 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABCA1 | SNV | Missense_Mutation | | c.127N>T | p.Arg43Trp | p.R43W | O95477 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.4231G>T | p.Asp1411Tyr | p.D1411Y | O95477 | protein_coding | deleterious(0) | benign(0.166) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.3883G>T | p.Asp1295Tyr | p.D1295Y | O95477 | protein_coding | deleterious(0.03) | benign(0.197) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | rs766712712 | c.5563N>A | p.Ala1855Thr | p.A1855T | O95477 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | novel | c.6500T>C | p.Val2167Ala | p.V2167A | O95477 | protein_coding | tolerated(0.28) | benign(0.027) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ABCA1 | SNV | Missense_Mutation | | c.4552N>A | p.Ala1518Thr | p.A1518T | O95477 | protein_coding | tolerated(0.07) | benign(0.026) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.4823N>C | p.Val1608Ala | p.V1608A | O95477 | protein_coding | deleterious(0.01) | benign(0.42) | TCGA-D1-A17M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.6041G>A | p.Arg2014Lys | p.R2014K | O95477 | protein_coding | tolerated(0.08) | probably_damaging(0.953) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.791G>T | p.Ser264Ile | p.S264I | O95477 | protein_coding | tolerated(0.08) | benign(0.092) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABCA1 | SNV | Missense_Mutation | | c.5342G>A | p.Gly1781Asp | p.G1781D | O95477 | protein_coding | deleterious(0.02) | possibly_damaging(0.908) | TCGA-D1-A17R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | pravastatin | PRAVASTATIN | 19673941,20031551 |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL608 | PROBUCOL | |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 178103851 | PROBUCOL | |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | fenofibrate | FENOFIBRATE | |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | 315661263 | | |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | atorvastatin | ATORVASTATIN | 20031551 |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CSA | CYCLOSPORINE | 15084924 |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | simvastatin | SIMVASTATIN | 20031551 |
19 | ABCA1 | TRANSPORTER, DRUGGABLE GENOME, ABC TRANSPORTER, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Probucol | PROBUCOL | |